Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: Preclinical and clinical outcomes.
Misfolded Proteins, Mitochondrial Dysfunction, and Neurodegenerative Diseases
Jin H1, Kanthasamy A, Ghosh A, Anantharam V, Kalyanaraman B, Kanthasamy AG
1 Parkinson’s Disorder Research Laboratory, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA.
Parkinson’s disease is a progressive neurodegenerative disease in the elderly, and no cure or disease-modifying therapies exist. Several lines of evidence suggest that mitochondrial dysfunction and oxidative stress have a central role in the dopaminergic neurodegeneration of Parkinson’s disease. In this context, mitochondria-targeted therapies that improve mitochondrial function may have great promise in the prevention and treatment of Parkinson’s disease. In this review, we discuss the recent developments in mitochondria-targeted antioxidants and their potential beneficial effects as a therapy for ameliorating mitochondrial dysfunction in Parkinson’s disease. This article is part of a Special Issue entitled: Misfolded Proteins, Mitochondrial Dysfunction and Neurodegenerative Diseases.